Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CFO Charles N. York II bought 25,959 shares of the firm’s stock in a transaction on Tuesday, December 5th. The shares were acquired at an average price of $4.48 per share, for a total transaction of $116,296.32. Following the transaction, the chief financial officer now owns 10,828 shares in the company, valued at $48,509.44. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) traded down $0.34 during trading hours on Tuesday, hitting $4.74. 76,239 shares of the company’s stock were exchanged, compared to its average volume of 65,901. Aeglea Bio Therapeutics Inc has a 1 year low of $2.81 and a 1 year high of $8.14.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.07. Aeglea Bio Therapeutics had a negative net margin of 527.99% and a negative return on equity of 44.05%. The firm had revenue of $1.26 million for the quarter. sell-side analysts expect that Aeglea Bio Therapeutics Inc will post -1.97 earnings per share for the current year.

Separately, Zacks Investment Research upgraded shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Friday, November 10th.

Several large investors have recently made changes to their positions in AGLE. Bank of New York Mellon Corp acquired a new stake in shares of Aeglea Bio Therapeutics during the 1st quarter worth approximately $157,000. Renaissance Technologies LLC acquired a new stake in shares of Aeglea Bio Therapeutics during the 1st quarter worth approximately $270,000. Vanguard Group Inc. boosted its position in shares of Aeglea Bio Therapeutics by 9.4% during the 2nd quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after acquiring an additional 12,966 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of Aeglea Bio Therapeutics during the 2nd quarter worth approximately $653,000. Hedge funds and other institutional investors own 46.89% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with's FREE daily email newsletter.